Understanding both intrinsic and acquired resistance to MEK inhibitors will be essential for defining effective clinical strategies that employ MEK inhibitors in KRAS mutant lung and other cancers, and improving overall patient outcomes. The gene discussed is MAP2K7; the disease is cancer.